OIG exposes ‘alarming’ misuse and masking of antipsychotic drug use in nursing homes
Key Questions
What did the OIG report reveal about antipsychotics in nursing homes?
Fake schizophrenia diagnoses to avoid citations and justify chemical restraints for dementia behaviors, ignoring FDA black-box death risks. CMS oversight gaps persist. Birx warns of ongoing issues.
Who is most affected by antipsychotic misuse in nursing homes?
Dementia patients, especially women 70+ at stroke risk. Reinforces Beers Criteria vigilance. Push non-drug alternatives.
What should families do about potential antipsychotic misuse?
Audit facilities, demand non-drug options for behaviors, monitor for side effects. Report concerns to CMS/OIG. Avoid psych med traps.
OIG report reveals fake schizophrenia diagnoses to dodge citations and enable chemical restraints for dementia behaviors, ignoring FDA death risks/side effects; Birx warns of ongoing risks; CMS gaps; stroke risks women 70+; dementia pts overprescribed brain meds (25% vs 17%). Reinforces Beers vigilance, push non-drug alternatives, audit facilities; psych med traps noted.